Table 4.

Yearly and overall ADD

Therapy	Cohort	ADD
		Overall			2015			2016			2017
		Mean	SD	Median	Mean	SD	Median	Mean	SD	Median	Mean	SD	Median
exBID	BE N = 68	17.03	3.32	16.71	18.32	3.44	17.83	16.08	2.66	16.56	16.62	3.94	15.03
	FR N = 487	13.21	0.91	13.03	12.65	0.72	12.48	12.83	0.36	12.92	14.23	0.67	13.97
	DE N = 2579	18.55	2.43	17.90	17.61	0.51	17.58	17.74	0.71	17.83	20.45	3.67	19.47
	IT N = 393	20.43	5.43	19.48	18.68	0.81	18.75	19.17	1.35	19.60	23.44	8.74	21.38
	NL N = 18	19.31	4.76	18.93	16.75	4.52	14.91	20.42	5.48	18.93	20.76	3.36	21.12
	CA N = 71	14.22	3.00	14.31	13.48	1.86	13.97	13.35	2.79	13.72	s
LIRA	BE N = 997	1.44	0.16	1.42	1.35	0.09	1.31	1.41	0.08	1.39	1.58	0.19	1.53
	FR N = 8012	1.51	0.14	1.49	1.41	0.04	1.42	1.49	0.03	1.49	1.64	0.16	1.59
	DE N = 15,792	1.61	0.41	1.48	1.41	0.04	1.41	1.48	0.04	1.48	1.93	0.60	1.61
	IT N = 9,557	1.54	0.17	1.51	1.42	0.04	1.42	1.50	0.03	1.50	1.70	0.21	1.62
	NL N = 1225	1.68	0.30	1.61	1.49	0.08	1.50	1.62	0.05	1.61	1.92	0.42	1.76
	CA N = 12,734	1.61	0.18	1.61	1.43	0.10	1.45	1.60	0.03	1.61	1.80	0.15	1.79
LIXI	BE N = 407	19.88	1.88	19.68	19.54	1.64	19.54	19.66	1.04	19.82	20.43	2.64	20.78
	IT N = 1772	20.07	2.31	19.76	18.92	0.53	19.04	19.90	0.27	19.93	21.39	3.65	20.34
	NL N = 25	20.54	4.19	19.99	20.51	5.33	18.78	20.21	4.31	19.59	21.02	2.55	20.36

ADD reported for exBID (µg), LIRA (mg), and LIXI (µg)

ADD presented represents a summary of monthly ADD for eligible prescription records. Patient N changes over time, and patients reflect a mix of new initiators and prevalent users over time

s  indicates that data were suppressed in Canada when the patient count was less than 5, in compliance with Canadian privacy legislation

BE Belgium, CA Canada, exBID exenatide twice daily, FR France, DE Germany, IT Italy, LIRA liraglutide, LIXI lixisenatide, µg micrograms, mg milligrams, NL Netherlands